NCT07379047 2026-01-30
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3 Not yet recruiting
Clinical Trials
12 trialsNCT06087263 2026-01-20
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05366816 2025-09-09
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2 Recruiting
NCT02365441 2023-07-07
ALT GIST
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT02638766 2023-03-27
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT01068769 2020-08-24
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02889328 2020-01-09
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Phase 2 Completed
NCT02606097 2019-03-21
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
Phase 2 Completed
NCT02800330 2018-08-02
REGORA
Erasmus Medical Center
Phase 4 Completed